Moreover, ANA title correlate with disease severity and progression17, 19 and molecular profiles are associated with ANA serotypes.20 21 Finally, patients with SSc may respond response to therapeutic targeting humoral immunity such as rituximab,22 23 and more recently anti-CD19 chimeric antigen receptors T cells.24 25. The gene discussed is CD19; the disease is systemic sclerosis.